

## **Association of Center-Level Operative Volume and Acute Outcomes following Robotic-Assisted Colectomy for Malignancy**

Nam Yong Cho BS<sup>1</sup>, Shineui Kim BA<sup>1</sup>, Joseph Hadaya MD<sup>1</sup>, Nikhil Chervu MD<sup>1</sup>,  
Shayan Ebrahimian MS<sup>1</sup>, Emma Cruz<sup>1</sup>, Hanjoo Lee MD<sup>2</sup>, Peyman Benharash MD<sup>1,3</sup>

<sup>1</sup>Cardiovascular Outcomes Research Laboratories (CORELAB), Division of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

<sup>2</sup>Division of Colorectal Surgery, UCLA-Harbor Medical Center, Los Angeles, CA

<sup>3</sup>Division of Cardiac Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

**Short Title:** Robotic-Assisted Colectomy for Malignancy: Contemporary Analysis of Center-Level Operative Volume

**Word Count:** Main Body 2287 Words; Abstract 234 Words

**Twitter:** Core Lab: [@CoreLabUCLA](#) | Nam Yong Cho: [@NamYong\\_Cho](#)

Corresponding Author:

Peyman Benharash, MD

10833 Le Conte Avenue

UCLA Center for Health Sciences, Room 62-249

Los Angeles, CA 90095

Phone: 310-206-6717

Fax: 310-206-5901

[Pbenharash@mednet.ucla.edu](mailto:Pbenharash@mednet.ucla.edu)

## Abstract

*Background:* The adoption of RAC remains limited due to high costs. There is a paucity of data regarding the impact of institutional robotic experience on costs in patients undergoing RAC for colorectal cancer.

*Methods:* All adult patients undergoing RAC for colorectal cancer were identified using the 2016-2020 Nationwide Readmissions Database. A multivariable regression to model major adverse events (MAE) was developed with the inclusion of institutional robotic surgery volume as restricted cubic splines. The volume corresponding to the inflection point of the spline was used to stratify hospitals into high- (HVH) or low-volume (LVH). We subsequently examined the association of HVH status with costs, length of stay (LOS), MAE, non-home discharge and 30-day unplanned readmission.

*Results:* Among the 43,475 patients undergoing RAC, 63.8% were treated at HVH. Following risk adjustment, RAC at HVH was associated with reduced index hospitalization costs by \$2,000 (95%CI \$1,500-2,400) and LOS by 0.3 days (95%CI 0.2-0.5 days) as well as decreased odds of MAE (AOR 0.86, 95%CI 0.77-0.96). Both non-home discharge and 30-day unplanned readmission were not associated with hospital volume. In our cross-volume analysis, we found an increase in institutional RAC and overall robotic volumes to be associated with reduced odds of MAE.

*Conclusion:* The present study demonstrated higher institutional robotic-assisted operation volume to be associated with reduced MAE and cost in patients undergoing

RAC. The findings suggest the potential benefits of increasing expertise and implementing efficient practices in robotic-assisted surgery programs.

**Keywords:** Colectomy, robotic-assisted surgery, laparoscopic colectomy, quality metrics, nationwide readmissions database

## Introduction:

Robotic-assisted surgery has been increasingly adopted in the United States and is now utilized in >15% of all general surgical procedures.<sup>1</sup> Compared to laparoscopy, robotic-assisted surgery allows for improved visualization, tremor control and greater range of motion given the use of wristed instruments. This technology has been employed in robotic-assisted colectomy (RAC), with its safety and feasibility widely established in the literature.<sup>2-5</sup> Prior work has highlighted the cost-effectiveness of the robotic-assisted colectomy despite similar average costs compared to the laparoscopic approach (costs: laparoscopic \$13,039, robotic \$13,529, open \$21,168).<sup>6</sup> Nonetheless, utilization of RAC in the United States is reported to be low, in part, due to the significant costs associated with acquisition and maintenance of robotic equipment.<sup>7-9</sup> Despite maturation of robotics and the potential for enhanced recovery, Simianu et al. reported RAC to remain less cost-effective compared to laparoscopy in the current era.<sup>10</sup>

Prior work has revealed higher center-specific robotic surgical volume to be associated with lower costs for various cancer operations including lobectomy and pancreaticoduodenectomy.<sup>11,12</sup> Specifically, an increase in the overall robotic-assisted caseloads have been shown to reduce operative times and postoperative length of stay.<sup>10</sup> However, there is a paucity of data regarding the definition of high-volume for RAC as well as its associated cost-volume outcome relationship. Moreover, whether this observation is mediated through RAC specific or overall robotic volume remains unclear. In the present study, we examined the association of institutional robotic-assisted surgery volume with clinical outcomes and various measures of resource use

in a national cohort of patients receiving RAC. We hypothesized greater institutional robotic-assisted operation volume to be associated with reduced mortality, complications, length of stay and 30-day unplanned readmissions.

### **Materials and Methods:**

This was a retrospective study of the 2016-2020 Nationwide Readmissions Database (NRD). The NRD is an all-payer readmissions database that provides accurate estimates for ~ 57% of all hospitalization across the United States using survey methodology. The NRD tracks readmissions across hospitals within each calendar year.<sup>13</sup> Using relevant *International Classification of Disease, 10th Revision* (ICD-10) codes, all adult ( $\geq 18$  years) hospitalizations entailing RAC (right hemicolectomy, transverse colectomy, left hemicolectomy, sigmoid colectomy and total colectomy) for benign or malignant colorectal neoplasms were identified (Supplemental Table S1). Records missing data for age, sex and charges, were excluded from analysis (0.01%; Figure 1).

Patient and hospital characteristics, including age, sex and zip code-based income level, were defined using the HCUP data dictionary.<sup>13</sup> The van Walraven modification of the Elixhauser Comorbidity Index was used to numerically capture the burden of chronic conditions.<sup>14</sup> Other clinically relevant comorbidities and complications were tabulated using ICD-10 codes.<sup>15</sup> Hospitalization costs were calculated by application of cost-to-charge ratios to total hospitalization charges and subsequent adjustment for inflation using the 2020 Personal Health Index.<sup>16</sup>

The overall hospital robotic case volume was calculated as the number of overall robotic-assisted operations performed at each institution each year. Similarly, institutional robotic-assisted colectomy volume was determined as the number of robotic-assisted colectomy cases performed yearly. As the NRD does not track hospitals across calendar years, caseload estimates were calculated independently for each year in the study. A logistic regression model for major adverse events (MAE) was developed with overall robotic-assisted operation case volume modeled as a restricted cubic spline. Of note, MAE was defined as a composite of in-hospital mortality and neurologic (stroke or transient ischemic attack), cardiovascular (cardiac arrest, myocardial infarction, ventricular arrhythmias, or tamponade), respiratory (acute respiratory failure, acute respiratory distress syndrome, prolonged ventilation greater than 96 hours, pneumonia, or pneumothorax), thromboembolic (deep venous thrombosis or pulmonary embolism), infectious (sepsis or surgical site infection) and gastrointestinal (anastomotic leak, gastrointestinal bleeding, gastrointestinal obstruction) complications. To facilitate comparison, the inflection point of this spline was used to designate institutions as high- (HVH) or low-volume hospitals (LVH). The primary outcome of the study was index hospitalization costs, while secondary outcomes included MAE, postoperative length of stay (LOS), non-home discharge and 30-day unplanned readmission.

Categorical variables are expressed as group proportions, while continuous variables are shown as medians with interquartile range (IQR). Comparisons by volume status were made using Pearson's  $\chi^2$ -test for categorical and the Mann-Whitney U test for continuous variables. Entropy balancing was utilized to generate a weighted

comparison group with similar distribution of covariates. Superior to propensity matching, this methodology seeks a set of sample weights that satisfy balance constraints while maintaining the entire cohort for analysis.<sup>17</sup> Multivariable linear and logistic regressions were subsequently developed to evaluate the association of HVH status with the outcomes of interest. Regression outputs are shown as adjusted odds ratios (AOR) or beta coefficients ( $\beta$ ), both with 95% confidence intervals (CI). To account for effect size, standardized mean difference (SMD)  $>0.10$  was utilized to demonstrate statistical significance. Data was gathered and reported according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guideline. All statistical analyses were performed using Stata 16.0 (StataCorp, College Station, TX). Data visualization was achieved using Python (Python Software Foundation) package *Matplotlib*. Due to the fully de-identified nature of the NRD, this study was deemed exempt from full review by the Institutional Review Board at the University of California, Los Angeles, Los Angeles, CA (IRB:17-001112, approved July 26, 2017).

## **Results:**

### *Study Cohort Baseline Characteristics at HVH and LVH*

Of an estimated 43,475 patients undergoing robotic-assisted colectomy for malignancy, 63.8% received care at HVH. Compared to LVH, patients at HVH were younger (64 [54-73] vs 66 [56-74] years, SMD=0.13), more often had private insurance (43.9 vs 37.4%, SMD=0.16) and often from highest income quartile (28.5 vs 23.7%, SMD=0.15). In addition, patients at HVH more frequently underwent RAC at urban

teaching (87.0 vs 69.9%, SMD=0.40) and large-bed hospitals (66.2 vs 51.5%, SMD=0.34) compared to those at LVH. Patients at LVH more commonly underwent RAC non-electively (86.7 vs 92.1%, SMD=0.18) compared to those at HVH. As shown on Table 1, patients undergoing RAC for malignancy at LVH had similar comorbidities including diabetes (23.1 vs 21.1%, SMD=0.05), congestive heart failure (4.2 vs 3.5%, SMD=0.04) and malnutrition (3.9 vs 3.7%, SMD=0.02).

	LVH (N=15,728)	HVH (N=27,747)	SMD
Age (year)	66 [56-74]	64 [54-73]	0.13
Female Sex (%)	47.4	47.3	0.002
Elective (%)	86.7	92.1	0.18
Elixhauser Index Score	3 [2-4]	3 [2-4]	0.05
Hospital Bed Size (%)			0.34
Small	17.8	9.0	
Medium	30.7	24.8	
Large	51.5	66.2	
Hospital Teaching Status (%)			0.40
Rural	6.6	1.3	
Urban Nonteaching	23.5	11.8	
Urban Teaching	69.9	87.0	
Insurance Status (%)			0.16
Medicare	51.8	47.6	
Medicaid	7.4	5.4	
Private	37.4	43.9	
Self-pay	1.2	1.3	
Income quartile (%)			0.15
0 - 25th	24.6	19.5	
25th - 50th	26.3	25.5	
50th - 75th	25.4	16.6	
75th - 100th	23.7	28.5	
Anemia (%)	9.0	8.4	0.03
Diabetes (%)	23.1	21.1	0.05
Heart Failure (%)	4.2	3.5	0.04
Malnutrition (%)	3.9	3.7	0.02
Obesity (%)	19.6	19.6	0.01
Smoking (%)	10.2	9.6	0.02



**Table 1.** Demographic of patients undergoing robotic colectomy stratified by management at stratified by low- (LVH) and high-volume hospital (HVH) designation. SMD, Standardized Mean Difference.

### *Outcomes at HVH and LVH*

On unadjusted analysis, patients undergoing RAC at HVH had lower index hospitalization costs (\$22,000 [16,800-30,000] vs \$23,300 [17,200-32,900]) compared to those at LVH. In addition, compared to those at LVH, patients at HVH had lower rates of MAE (7.2 vs 8.9%). Patients undergoing RAC at HVH had lower hospital duration of stay (3 [2-5] vs 4 [3-6] days) while rates of 30-day unplanned readmission (7.0 vs 7.4%) were similar compared to LVH (Table 2). Following RAC, patients at HVH had lower rates of non-home discharge (4.4 vs 5.3%) than others.

**Table 2.** Unadjusted analysis of clinical and financial outcomes in patients undergoing robotic-assisted colectomy stratified by low- (LVH) and high-volume hospital (HVH) designation. D, Days. Comparison of categorical variables is reported using 95% confidence intervals while that of continuous variables are shown with median and interquartile range.

	<b>LVH (N=15,728)</b>	<b>HVH (N=27,747)</b>
Major Adverse Event (%)	8.9 (8.3-9.4)	7.2 (6.7-7.5)
Mortality (%)	0.6 (0.4-0.7)	0.3 (0.2-0.4)
Conversion to Open (%)	0.4 (0.3-0.5)	0.4 (0.3-0.5)
Cost (\$1,000)	23.3 [17.2-32.9]	22.0 [16.8-30.0]
LOS (d)	4 [3-6]	3 [2-5]
Readmission in 30 Days (%)	7.9 (7.3-8.3)	7.6 (7.0-7.9)
Nonhome Discharge (%)	5.3 (4.7-5.6)	4.4 (4.0-4.6)

Following risk adjustment, RAC at HVH was associated with reduced index hospitalization costs by \$2,000 (95%CI \$1,500-2,400). Factors associated with an increment in hospitalization costs included insurance status with Medicaid ( $\beta$  \$4,100, 95%CI \$3,200-5,000), highest income quartile ( $\beta$  \$5,700, 95%CI \$5,000-6,300) and large hospital bed size ( $\beta$  \$2,700, 95%CI \$2,000-2,700). Conversion to laparotomy was also associated with increased hospitalization costs by \$14,000 (95%CI \$10,500-17,600). On our spline analysis, HVH demonstrated lower likelihood of MAE compared to LVH, as shown in Figure 2. Management at HVH was associated with significantly reduced odds of mortality (AOR 0.63, 95%CI 0.40-0.99) while odds of conversion to open procedures (AOR 1.01, 95%CI 0.65-1.58) were similar. Furthermore, HVH status was associated with a 0.3-day decrement in LOS (95%CI 0.2-0.5 days). Both non-home discharge and 30-day unplanned readmission and were not associated with hospital volume (Table 3).

**Table 3.** Risk-adjusted analysis of clinical and financial outcomes in patients undergoing robotic-assisted colectomy at high-volume hospitals. D, Days. Estimates are reported as adjusted odds ratio (AOR) for dichotomous outcomes and  $\beta$ -coefficients for continuous outcomes with corresponding 95% confidence interval for both (Reference: low-volume hospital).

	<b>Estimates (<math>\beta</math>/AOR)</b>	<b>95%CI</b>
Major Adverse Event	0.86*	0.77-0.96
Mortality	0.63*	0.40-0.99
Conversion to Open	1.01	0.65-1.58
Cost (\$1,000)	-2.0*	-2.4--1.5
LOS (d)	-0.3*	-0.5--0.2
Readmission in 30 Days	0.97	0.91-1.04
Nonhome Discharge	0.90	0.79-1.02

### *Cross-Volume Analysis*

Following adjustment for patient and operative characteristics, the relationship between institutional RAC and overall robotic operation volumes was analyzed in regard to MAE. As shown in Figure 3, both an increase in institutional RAC and overall robotic operation volumes were found to be associated with reduced odds of MAE.

### **Discussion:**

In the present study, we examined the impact of institutional robotic-assisted operation volume on various clinical and financial endpoints following RAC for malignancy. We found that increasing overall robotic-assisted operation volume to be associated with a non-linear decrease in major adverse events. Additionally, high overall robotic-assisted operative volume was associated with decreased index hospitalization costs following RAC in our analysis. Notably, patients who underwent RAC at HVH experienced lower rates of MAE and shorter hospital duration of stay. We performed a cross-volume analysis and found overall robotic volume and RAC volume to have a synergistic effect. Specifically, as the volume of operations increased, there was a corresponding decrease in the incidence of MAE. These findings warrant further discussion.

Previous studies have reported high overall robotic-assisted surgical volume to be associated with reduced costs for cancer surgery, including lobectomy, pancreaticoduodenectomy and prostatectomy.<sup>11,12,18,19</sup> In the present work on RAC, we found that an increase in the number of all robotic operations performed at a center was associated with decreased index hospitalization costs. This finding may be explained by

the fact that centers with a high robotic operation volume also tend to be high-volume colectomy institutions. While adoption community centers with low annual colectomy caseloads may have financial disadvantages, high-volume hospitals can likely afford robotic platforms. Furthermore, institutions with higher-volume colectomy volume may have enhanced integrated networks providing comprehensive cancer services or are academic centers with high rates of referral for RAC.<sup>21</sup> At such centers, prior studies have consistently demonstrated an inverse relationship between institutional surgical volume and operative time across various procedures including laparoscopic colectomy, which may ultimately reduce cost.<sup>21–23</sup> Other significant factors contributing to cost reduction include the implementation of streamlined practices at both hospital and operating room levels.<sup>24</sup> Notably, the adoption of prehabilitation protocols in many high-volume colectomy hospitals has been shown to reduce the rates of liver metastasis.<sup>25–27</sup> Common cost reduction strategies focus on minimizing instrument redundancies and improving operative efficiency, both of which can be achieved through the growing proficiency of surgeons with training and experience.<sup>28,29</sup> Further investigation to comprehensively identify factors contributing to the observed relationship between robotic operative volume and costs is warranted.

One potential mechanism for reducing inpatient costs is the reduced rates of MAE at high-volume RAC centers. Consistent with our study, Keller et al. analyzed 18 months of a national inpatient database, demonstrating both high RAC case and surgeon volumes to be associated with decreased perioperative complications.<sup>30</sup> Additionally, high robotic-assisted operative volumes were associated with lower rates of postoperative ileus and anastomotic leak, as well as shorter hospital stays and lower

costs following RAC.<sup>30</sup> These findings are substantiated by several factors, including improved infrastructure and shorter learning curves observed in high-volume hospitals specifically for RAC.<sup>30,31</sup> We hypothesize that center-specific experiences of surgeons at high-volume RAC hospitals are the main drivers of decreasing complication rates.<sup>32</sup> A prior study evaluating the outcomes of colorectal surgery for rectal cancer has found the lowest complication rate among patients operated on by high-volume surgeons.<sup>33</sup> Undoubtedly, shortened learning curve by the surgeon and the operating room staff for RAC contributes to decreased rates of perioperative complications and, consequently, reduced costs.<sup>30,32</sup>

Despite the rapid expansion of robotic surgery, we noted the majority of the RAC to be performed at low volume institutions. This finding emphasizes the need for streamlined robotic surgery infrastructures even in low volume hospitals. For instance, Swedish hospitals were able to maintain equal, sometimes better outcomes than Dutch hospitals despite having lower volume and later adoption of robotic surgery. The authors attributed this to the standardized training programs and higher per-surgeon volume in Sweden, which led to a shorter learning curve.<sup>34</sup> Appropriate patient selection during the early phases of the adoption of a robotic program has been proposed to lower MAE and cost. In an Austrian study evaluating the implementation of a robotic surgery program, MAE was particularly pronounced in complex cases during the early phases of enrollment. The authors recommended proceeding with simple cases and gradually building up to cases with higher complexity as the robotic program matures.<sup>35</sup> In order to improve infrastructure and shorten the learning curve at LVHs, these approaches can effectively support the objectives of value-based healthcare delivery.

The adoption of robotic surgery programs has been met with considerable debate, with challenges stemming from the inherent difficulties of converting robotic surgery to laparotomies and the high costs associated with maintaining the device.<sup>36</sup> Nonetheless, a recent Canadian study from a large tertiary center showed that the hospitalization cost trended downward after the robotic colorectal program was implemented.<sup>37</sup> The cost of robotic surgery was effectively mitigated through rigorous training of operating room staff and utilization of established postoperative care pathways, which led to a decrease in laparotomy conversion rates.<sup>37</sup> Our findings complement this by suggesting the strategic distribution of robotic technology across various operations may be a crucial structural factor that makes robotic surgery programs successful. Appropriate allocation of robotic operations to centers with high-case volumes and skilled surgeons will ensure familiarity with procedures and treatment pathways throughout the hospital system.<sup>38</sup> For example, in the Netherlands, the number of hospitals performing robotic rectal cancer surgeries decreased between 2012 and 2018 despite an overall increase in the volume of overall surgical operations.<sup>34</sup> This was achieved by centralizing care at high-volume centers. However, such a national-level paradigm shift may not be feasible in the U.S., where healthcare delivery is still largely privatized and centralization may impair access to care.<sup>39,40</sup> Nonetheless, adoption of minimally invasive further studies are necessary to establish safe and cost-effective protocols for robotic surgery as it continues to advance in technology.

The present study has several noteworthy limitations. Due to the administrative nature of the NRD, our access to detailed clinical data, including laboratory values and oncologic staging for patients undergoing RAC, is limited. Additionally, the NRD lacks

the capability to evaluate institutional surgeon and center experience on robotic-assisted colectomy as well as their learning curve over the study period. Moreover, the absence of hospital region information in the NRD hinders our ability to assess geographic variations in costs. Notably, the charge data provided by the NRD does not offer a detailed breakdown of operating room costs or long-term expenditures associated with the robotic system or acquisition at particular institutions. As we defined high RAC volume based on MAE, our specific cut-off may not be applicable to other hospital-level performance. Despite these limitations, we used appropriate methodologies to show the relationship between robotic-assisted operative volume and inpatient costs at a large scale.

### **Conclusions:**

In this nationwide retrospective study, we examined the association of overall hospital robotic-assisted operative volume on clinical and financial outcomes following RAC for colorectal cancer. We found increased robotic-assisted operation volume to be significantly associated with decreased index hospitalization costs, lower rates of MAE and shorter LOS. Additionally, our study showed a synergistic effect between overall robotic-assisted operation volume and the institutional caseload of robotic-assisted colectomies in reducing the odds of MAE. These findings highlight the potential benefits that may derive from increased institutional expertise and the implementation of streamlined practices of robotic-assisted surgery. In light of the evolving landscape of value-based healthcare delivery, our study may supplement healthcare leaders in

making informed decisions regarding the incorporation of robotic-assisted surgery into their practices.



## **Acknowledgements**

None

## Reference

1. Sheetz KH, Claflin J, Dimick JB. Trends in the Adoption of Robotic Surgery for Common Surgical Procedures. *JAMA Netw Open*. 2020;3(1):e1918911. doi:10.1001/jamanetworkopen.2019.18911
2. Corcione F, Esposito C, Cuccurullo D, et al. Advantages and limits of robot-assisted laparoscopic surgery: preliminary experience. *Surg Endosc Interv Tech*. 2005;19(1):117-119. doi:10.1007/s00464-004-9004-9
3. Sheetz KH, Norton EC, Birkmeyer JD, Dimick JB. Provider Experience and the Comparative Safety of Laparoscopic and Open Colectomy. *Health Serv Res*. 2017;52(1):56-73. doi:10.1111/1475-6773.12482
4. deSouza AL, Prasad LM, Park JJ, Marecik SJ, Blumetti J, Abcarian H. Robotic assistance in right hemicolectomy: is there a role? *Dis Colon Rectum*. 2010;53(7):1000-1006. doi:10.1007/DCR.0b013e3181d32096
5. Robotic right colectomy using the Da Vinci Single-Site® platform: case report - Morelli - 2013 - The International Journal of Medical Robotics and Computer Assisted Surgery - Wiley Online Library. Accessed July 25, 2023. <https://onlinelibrary.wiley.com/doi/full/10.1002/rcs.1488>
6. Hancock KJ, Klimberg VS, Nunez-Lopez O, et al. Optimizing outcomes in colorectal surgery: cost and clinical analysis of robotic versus laparoscopic approaches to colon resection. *J Robot Surg*. 2022;16(1):107-112. doi:10.1007/s11701-021-01205-8
7. Deutsch GB, Sathyanarayana SA, Gunabushanam V, et al. Robotic vs. laparoscopic colorectal surgery: an institutional experience. *Surg Endosc*. 2012;26(4):956-963. doi:10.1007/s00464-011-1977-6
8. Robinson CN, Chen GJ, Balentine CJ, et al. Minimally invasive surgery is underutilized for colon cancer. *Ann Surg Oncol*. 2011;18(5):1412-1418. doi:10.1245/s10434-010-1479-0
9. Hamed OH, Gusani NJ, Kimchi ET, Kavic SM. Minimally Invasive Surgery in Gastrointestinal Cancer: Benefits, Challenges, and Solutions for Underutilization. *JLS*. 2014;18(4):e2014.00134. doi:10.4293/JLS.2014.00134
10. Simianu VV, Gaertner WB, Kuntz K, et al. Cost-effectiveness Evaluation of Laparoscopic Versus Robotic Minimally Invasive Colectomy. *Ann Surg*. 2020;272(2):334. doi:10.1097/SLA.0000000000003196
11. Verma A, Hadaya J, Richardson S, et al. The Presence of Cost-Volume Relationship in Robotic-Assisted Thoracoscopic Lung Resections. *Ann Surg*. Published online September 8, 2022. doi:10.1097/SLA.0000000000005699

12. Adam MA, Thomas S, Youngwirth L, Pappas T, Roman SA, Sosa JA. Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States. *JAMA Surg*. 2017;152(4):336-342. doi:10.1001/jamasurg.2016.4753
13. NRD Overview. Accessed May 13, 2023. <https://hcup-us.ahrq.gov/nrdoverview.jsp>
14. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A Modification of the Elixhauser Comorbidity Measures into a Point System for Hospital Death Using Administrative Data. *Med Care*. 2009;47(6):626-633.
15. Madrigal J, Tran Z, Hadaya J, Sanaiha Y, Benharash P. Impact of Chronic Lymphocytic Leukemia on Outcomes and Readmissions After Cardiac Operations. *Ann Thorac Surg*. 2022;114(1):152-159. doi:10.1016/j.athoracsur.2021.07.059
16. Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP). Published November 3, 2021. Accessed October 3, 2022. <https://hcup-us.ahrq.gov/db/ccr/costtocharge.jsp>
17. Hainmueller J. Entropy Balancing for Causal Effects: A Multivariate Reweighting Method to Produce Balanced Samples in Observational Studies. *Polit Anal*. 2012;20(1):25-46. doi:10.1093/pan/mpr025
18. Enomoto LM, Gusani NJ, Dillon PW, Hollenbeak CS. Impact of Surgeon and Hospital Volume on Mortality, Length of Stay, and Cost of Pancreaticoduodenectomy. *J Gastrointest Surg*. 2014;18(4):690-700. doi:10.1007/s11605-013-2422-z
19. Marcolino, Miriam Allein Zago, et al. "Cost-Effectiveness Analysis of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer From the Brazilian Public System Perspective." *Value in Health Regional Issues*, vol. 33, Jan. 2023, pp. 7–9. DOI.org (Crossref), <https://doi.org/10.1016/j.vhri.2022.08.007>.
20. Tunitsky E, Cital A, Ayaz R, Esin S, Knee A, Harmanli O. Does surgical volume influence short-term outcomes of laparoscopic hysterectomy? *Am J Obstet Gynecol*. 2010;203(1):24.e1-24.e6. doi:10.1016/j.ajog.2010.01.070
21. Villano AM, Zeymo A, Houlihan BK, Bayasi M, Al-Refaie WB, Chan KS. Minimally invasive surgery for colorectal cancer: hospital type drives utilization and outcomes. *Journal of Surgical Research*. 2020;247:180-189. doi:10.1016/j.jss.2019.07.102
22. Yasunaga H, Matsuyama Y, Ohe K, Japan Surgical Society. Effects of hospital and surgeon volumes on operating times, postoperative complications, and length of stay following laparoscopic colectomy. *Surg Today*. 2009;39(11):955-961. doi:10.1007/s00595-008-4052-8
23. Mowat A, Maher C, Ballard E. Surgical outcomes for low-volume vs high-volume surgeons in gynecology surgery: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2016;215(1):21-33. doi:10.1016/j.ajog.2016.02.048

24. Dyas AR, Lovell KM, Balentine CJ, et al. Reducing cost and improving operating room efficiency: examination of surgical instrument processing. *J Surg Res*. 2018;229:15-19. doi:10.1016/j.jss.2018.03.038
25. Trépanier M, Minnella EM, Paradis T, et al. Improved Disease-free Survival After Prehabilitation for Colorectal Cancer Surgery. *Ann Surg*. 2019;270(3):493. doi:10.1097/SLA.0000000000003465
26. Chow FCL, Chok KSH. Colorectal liver metastases: An update on multidisciplinary approach. *World J Hepatol*. 2019;11(2):150-172. doi:10.4254/wjh.v11.i2.150
27. van Gijn W, Gooiker GA, Wouters MWJM, Post PN, Tollenaar RAEM, van de Velde CJH. Volume and outcome in colorectal cancer surgery. *Eur J Surg Oncol EJSO*. 2010;36:S55-S63. doi:10.1016/j.ejso.2010.06.027
28. Bokhari MB, Patel CB, Ramos-Valadez DI, Ragupathi M, Haas EM. Learning curve for robotic-assisted laparoscopic colorectal surgery. *Surg Endosc*. 2011;25(3):855-860. doi:10.1007/s00464-010-1281-x
29. Rashidi L, Neighorn C, Bastawrous A. Outcome comparisons between high-volume robotic and laparoscopic surgeons in a large healthcare system. *Am J Surg*. 2017;213(5):901-905. doi:10.1016/j.amjsurg.2017.03.034
30. Keller DS, Hashemi L, Lu M, Delaney CP. Short-Term Outcomes for Robotic Colorectal Surgery by Provider Volume. *J Am Coll Surg*. 2013;217(6):1063-1069.e1. doi:10.1016/j.jamcollsurg.2013.07.390
31. Acher AW, Weber SM, Pawlik TM. Does the Volume-Outcome Association in Pancreas Cancer Surgery Justify Regionalization of Care? A Review of Current Controversies. *Ann Surg Oncol*. 2022;29(2):1257-1268. doi:10.1245/s10434-021-10765-w
32. Harmon JW, Tang DG, Gordon TA, et al. Hospital Volume Can Serve as a Surrogate for Surgeon Volume for Achieving Excellent Outcomes in Colorectal Resection. *Ann Surg*. 1999;230(3):404.
33. Billingsley KG, Morris AM, Green P, et al. Does Surgeon Case Volume Influence Nonfatal Adverse Outcomes after Rectal Cancer Resection? *J Am Coll Surg*. 2008;206(6):1167-1177. doi:10.1016/j.jamcollsurg.2007.12.042
34. Warps AK, Saraste D, Westerterp M, et al. National differences in implementation of minimally invasive surgery for colorectal cancer and the influence on short-term outcomes. *Surg Endosc*. 2022;36(8):5986-6001. doi:10.1007/s00464-021-08974-1
35. Müller C, Laengle J, Riss S, Bergmann M, Bachleitner-Hofmann T. Surgical Complexity and Outcome During the Implementation Phase of a Robotic Colorectal Surgery Program—A Retrospective Cohort Study. *Front Oncol*. 2021;10. Accessed July 25, 2023. <https://www.frontiersin.org/articles/10.3389/fonc.2020.603216>

36. Park JS, Choi GS, Park SY, Kim HJ, Ryuk JP. Randomized clinical trial of robot-assisted versus standard laparoscopic right colectomy. *Br J Surg*. 2012;99(9):1219-1226. doi:10.1002/bjs.8841
37. Patel SV, Wiseman V, Zhang L, et al. The impact of robotic surgery on a tertiary care colorectal surgery program, an assessment of costs and short term outcomes: A Canadian perspective. *Surg Endosc*. 2022;36(8):6084-6094. doi:10.1007/s00464-022-09059-3
38. Liberman D, Trinh QD, Jeldres C, Zorn KC. Is robotic surgery cost-effective: yes. *Curr Opin Urol*. 2012;22(1):61. doi:10.1097/MOU.0b013e32834d543f
39. McGlynn EA, Asch SM, Adams J, et al. The Quality of Health Care Delivered to Adults in the United States. *N Engl J Med*. 2003;348(26):2635-2645. doi:10.1056/NEJMsa022615
40. Keane MP, McCormick B, Popławska G. Health care spending in the US vs UK: The roles of medical education costs, malpractice risk and defensive medicine. *Eur Econ Rev*. 2020;124:103401. doi:10.1016/j.euroecorev.2020.103401

## **Supporting Information**

### **Study Type**

Retrospective cohort study

### **Disclosures**

Nam Yong Cho – None

Shineui Kim – None

Joseph Hadaya MD – None

Nikhil Chervu MD – None

Shayan Ebrahimian MS – None

Emma Cruz – None

Hanjoo Lee MD – None

Peyman Benharash MD – Dr. Peyman Benharash received proctor fees from Atricure as a surgical proctor. This manuscript does not discuss any Atricure products or services. Other authors report no conflicts.

### **Author Contributions**

**Nam Yong Cho:** Conceptualization, Methodology, Data Analysis, Writing Original Draft.

**Shineui Kim:** Data Analysis, Reviewing, Editing. **Joseph Hadaya:** Methodology, Validation, Editing. **Nikhil Chervu:** Conceptualization, Writing. **Shayan Ebrahimian:**


Writing, Software. **Emma Cruz:** Generating Tables/Figures. **Hanjoo Lee:** Reviewing, Editing. **Peyman Benharash:** Conceptualization, Methodology, Supervision, Reviewing.

## Figure Legends

Figure 1. Flow diagram of study cohort and survey-weighted sample size.

Figure 2. Spline analysis of risk-adjusted major adverse event (MAE) following robotic-assisted colectomy stratified by overall robotic operation caseload.

Figure 3. Surface plot demonstrating the relationship of institutional robotic colectomy caseload and overall robotic operation caseload with major adverse events.





Nationwide Readmission Database 2016-2020  
Robotic-Assisted Colectomy (N=91,959)

Exclusion Criteria  
No Cancer diagnosis  
<18 Years  
Missing data on age, sex or cost

Robotic-Assisted Colectomy  
(N=43,475)

Low-Volume Hospitals  
(N=15,728)

High-Volume Hospitals  
(N=27,747)

